Review Article

A Survey of Strategies to Modulate the Bone Morphogenetic Protein Signaling Pathway: Current and Future Perspectives

Table 4

Small molecule inhibitors of BMP Type 1 receptors and examples of their use.

MoleculeComment(s)Reference(s)

1LWYDramatically enhanced selectivity for ALK2 versus other type 1 BMP receptors (approximate order of selectivity: ALK2 > ALK3 > ALK6); greatly reduced off-target effects compared to DM and LDN[120]

DMH1Pan-type 1 BMP receptor inhibitor (approximate order of selectivity: ALK3 > ALK1 > ALK6 > ALK2); reduced off-target effects compared to DM and LDN[121, 122, 201205]

DMH2Pan-type 1 BMP receptor inhibitor (approximate order selectivity: ALK6 > ALK3 > ALK2); notable off-target effects, including BMPR2, TGFBR2, ALK4, ALK5, AMPK, and VEGFR2[120, 201, 206]

DMH3Presumed pan-type 1 BMP receptor inhibitor; reduced off-target effects compared to DM and LDN[201]

Dorsomorphin (DM)Pan-type 1 BMP receptor inhibitor (approximate order of selectivity: ALK2 > ALK3 > ALK1 > ALK6); notable off-target effects, including BMPR2, ACVR2A, ACVR2B, TGFBR2, ALK5, AMPK, VEGFR2, and PDGFRβ[114, 121, 122, 124, 201, 202, 207215]

K02288Modestly enhanced selectivity for ALK1 and ALK2 versus other type 1 BMP receptors (approximate order of selectivity: ALK2 > ALK1 > ALK6 > ALK3); reduced off-target effects compared to DM and LDN[121, 216, 217]

LDN-193189 (LDN)Pan-type 1 BMP receptor inhibitor (approximate order of selectivity: ALK1~ALK2 > ALK3 > ALK6); notable off-target effects, including BMPR2, ACVR2A, ACVR2B, TGFBR2, ALK5, AMPK, VEGFR2, and PDGFRβ[120122, 124, 185, 191, 207209, 216, 218227]

LDN-212854Significantly enhanced selectivity for ALK1 and ALK2 versus other type 1 BMP receptors (approximate order of selectivity: ALK2 > ALK1 > ALK3); reduced off-target effects compared to DM and LDN[121]

LDN-214117Dramatically enhanced selectivity for ALK2 versus other type 1 BMP receptors (approximate order of selectivity: ALK1, ALK2 > ALK3); greatly reduced off-target effects compared to DM and LDN[123]

ML-347Dramatically enhanced selectivity for ALK1 and ALK2 versus other type 1 BMP receptors (approximate order of selectivity: ALK2 > ALK1 ≫ ALK3); reduced off-target effects compared to DM and LDN[122, 228]

VU5350Pan-type 1 BMP receptor inhibitor (approximate order selectivity: ALK3 > ALK2 > ALK6); notable off-target effects, including BMPR2, TGFBR2, AMPK, and VEGFR2[120]